View Main Condition: Brain Tumor
Sabine Mueller is a Neurologist and a Pediatrics expert in San Francisco, California. Mueller has been practicing medicine for over 20 years and is rated as an Elite expert by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. She is also highly rated in 15 other conditions, according to our data. Her top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Brain Stem Cancer, Brain Tumor, and Posterior Fossa Tumor. She is licensed to treat patients in California. Mueller is currently accepting new patients.
Katherine Warren is a Pediatric Hematologist Oncology specialist and a Pediatrics expert in Boston, Massachusetts. Warren is rated as an Elite expert by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. She is also highly rated in 9 other conditions, according to our data. Her top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Brain Stem Cancer, Glioma, Gliomatosis Cerebri, and Bone Marrow Transplant. She is licensed to treat patients in Massachusetts. Warren is currently accepting new patients.
Oren Becher is a Pediatric Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Becher has been practicing medicine for over 23 years and is rated as an Elite expert by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 10 other conditions, according to our data. His top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Brain Stem Cancer, Glioma, Posterior Fossa Tumor, and Bone Marrow Transplant. He is licensed to treat patients in New York. Becher is currently accepting new patients.
Summary: This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation. It also tests whether combination of selinexor and standard radiation therapy works to shrink...
Summary: The primary purpose of this study is to test whether GD2-CAR T cells can be successfully made from immune cells collected from children and young adults with H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) or spinal H3K27M-mutant diffuse midline glioma (DMG). H3K27Mmutant testing will occur as part of standard of care prior to enrollment.
Keep Punching supports patients, healthcare providers, and researchers in their fight to prevent and eradicate brain cancer and minimize treatment-related side effects that may adversely impact function and comfort.